A Phase 2 interventional study of New formulation adalimumab in Rheumatoid Arthritis, sponsored by AbbVie (prior sponsor, Abbott). Completed at 20 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-29.
Sponsored by AbbVie (prior sponsor, Abbott) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies testing adalimumab in Arthritis, Rheumatoid — 4 open to participants now, 6 under way, 2 of them phase 3. Adalimumab · Arthritis, Rheumatoid.
Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, this one is the 56th largest by enrollment, is one of 4 that started in 2012, is one of 9 in phase 2, and was the 50th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →4 of the 87 studies testing adalimumab in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Medical Center Groningen · Sites in Netherlands
Ages 18+
Qilu Hospital of Shandong University · Sites in China
Ages 18–80
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 12 · Phase 3 39 · Phase 4 33
First in 2000; this study’s year is marked. 4 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 88 is close to the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 160 across the 87 interventional studies. Of the 73 that completed or were terminated, 43 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 87 have an industry lead sponsor. The 10 most frequent:
This study is registered under AbbVie (prior sponsor, Abbott), one of the names counted as AbbVie. Under that name alone:
AbbVie (prior sponsor, Abbott) is the lead sponsor of 223 studies on the registry; none are open to participants now.
80 studies in Arthritis, Rheumatoid by AbbVie: 5 open now, 6 under way, 1 of them phase 3. Of 71 finished, 54 (76%) have results posted.
Among the 80 studies in Arthritis, Rheumatoid by AbbVie, this one is the 26th largest by enrollment of the 38 interventional ones that give a count, is one of 8 that started in 2012, is one of 16 in phase 2, and was the 32nd registered.
AbbVie’s Arthritis, Rheumatoid studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 80 in Arthritis, Rheumatoid:
This tab as a report to print or save as PDF → With an account.
A Phase 2b, open-label extension (OLE) study in rheumatoid arthritis (RA) patients designed to collect long-term safety, tolerability, efficacy, and immunogenicity data of the proposed new adalimumab formulation.
All participants who completed Study NCT01712178 had an opportunity to enroll into the study and to receive the new adalimumab formulation at a dose of 40 mg every other week (eow) for an additional 24 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
If female, subject is either not of , defined as for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy and/or hysterectomy) or is of childbearing potential and is practicing an approved method of throughout the study and for 150 days after last dose of study drug. Examples of approved methods of birth control include the following (see local for more detail):
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
New formulation adalimumab 40 mg every other week
Biological: New formulation adalimumab
New formulation adalimumab 40 mg every other week
Also known as: Humira
Mean Change From Baseline in Disease Activity Score 28 (DAS28) at Weeks 36 and 48
The Disease Activity Score (DAS28) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission.
Time frame: Baseline (Study NCT01712178 Week 0 Visit), Weeks 36 and 48
Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Weeks 36 and 48
American College of Rheumatology 20% (ACR20) response. A participant is a responder if the following 3 criteria for improvement from baseline are met: * ≥ 20% improvement in tender joint count; * ≥ 20% improvement in swollen joint count; and * ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Disability Index of the Health Assessment * CRP (Acute phase reactant (Erythrocyte sedimentation rate/C-reactive protein))
Time frame: Baseline (Study NCT01712178 Week 0 Visit), Weeks 36 and 48
Percentage of Participants With an American College of Rheumatology (ACR) 50 Response at Weeks 36 and 48
American College of Rheumatology 50% (ACR50) response. A participant is a responder if the following 3 criteria for improvement from baseline are met: * ≥ 50% improvement in tender joint count; * ≥ 50% improvement in swollen joint count; and * ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Disability Index of the Health Assessment * CRP (Acute phase reactant (Erythrocyte sedimentation rate/C-reactive protein))
Time frame: Baseline (Study NCT01712178 Week 0 Visit), Weeks 36 and 48
Mean Change From Baseline in Health Assessment Questionnaire (HAQ-DI) at Weeks 36 and 48
The Health Assessment Questionnaire - Disability Index (HAQ-DI) is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. The minimal clinically important difference (MCID) defined for the HAQ-DI is 0.22. HAQ remission indicating normal physical function is defined by HAQ-DI \< 0.5.
Time frame: Baseline (Study NCT01712178 Week 0 Visit), Weeks 36 and 48
Percentage of Participants Positive for Anti-adalimumab Antibody
Percentage of participants with anti-adalimumab antibody
Time frame: Week 24 through Week 48
| Milestone | New Formulation for 48 Weeks | Current Formulation for 24 Weeks, New Formulation for 24 Weeks |
|---|---|---|
| Started | 44 | 44 |
| Completed | 43 | 40 |
| Not completed | 1 | 4 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Withdrew consent | 0 | 2 |
| Withdrew: Lack of efficacy | 0 | 2 |
The Disease Activity Score (DAS28) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission.
| units on a scale | New Formulation for 48 Weeks | Current Formulation for 24 Weeks, New Formulation for 24 Weeks |
|---|---|---|
| Week 36 | -2.4 ± 1.17 | -2.2 ± 1.05 |
| Week 48 | -2.4 ± 1.29 | -2.2 ± 1.28 |
American College of Rheumatology 20% (ACR20) response. A participant is a responder if the following 3 criteria for improvement from baseline are met: * ≥ 20% improvement in tender joint count; * ≥ 20% improvement in swollen joint count; and * ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Disability Index of the Health Assessment * CRP (Acute phase reactant (Erythrocyte sedimentation rate/C-reactive protein))
| percentage of participants | New Formulation for 48 Weeks | Current Formulation for 24 Weeks, New Formulation for 24 Weeks |
|---|---|---|
| Week 36 | 72.7 | 76.7 |
| Week 48 | 74.4 | 80.0 |
American College of Rheumatology 50% (ACR50) response. A participant is a responder if the following 3 criteria for improvement from baseline are met: * ≥ 50% improvement in tender joint count; * ≥ 50% improvement in swollen joint count; and * ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Disability Index of the Health Assessment * CRP (Acute phase reactant (Erythrocyte sedimentation rate/C-reactive protein))
| percentage of participants | New Formulation for 48 Weeks | Current Formulation for 24 Weeks, New Formulation for 24 Weeks |
|---|---|---|
| Week 36 | 50.0 | 51.2 |
| Week 48 | 53.5 | 57.5 |
The Health Assessment Questionnaire - Disability Index (HAQ-DI) is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. The minimal clinically important difference (MCID) defined for the HAQ-DI is 0.22. HAQ remission indicating normal physical function is defined by HAQ-DI \< 0.5.
| units on a scale | New Formulation for 48 Weeks | Current Formulation for 24 Weeks, New Formulation for 24 Weeks |
|---|---|---|
| Week 36 | -0.5 ± 0.60 | -0.5 ± 0.69 |
| Week 48 | -0.5 ± 0.57 | -0.5 ± 0.58 |
Percentage of participants with anti-adalimumab antibody
| percentage of participants | New Formulation for 48 Weeks | Current Formulation for 24 Weeks, New Formulation for 24 Weeks |
|---|---|---|
| Percentage of Participants Positive for Anti-adalimumab Antibody | 13.6 | 18.2 |
Collected over Adverse events were collected from the time of study drug administration until 70 days following the last dose, approximately 58 weeks. Serious adverse events were collected from the time the participant signed the informed consent.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| New Formulation for 48 Weeks | — | 2/44 (4.5%) | 18/44 (40.9%) |
| Current Formulation for 24 Weeks, New Formulation for 24 Weeks | — | 1/44 (2.3%) | 19/44 (43.2%) |
| Event | New Formulation for 48 Weeks | Current Formulation for 24 Weeks, New Formulation for 24 Weeks |
|---|---|---|
| IRON DEFICIENCY ANAEMIABlood and lymphatic system disorders | 1/44 | 0/44 |
| ATRIAL FIBRILLATIONCardiac disorders | 1/44 | 0/44 |
| OSTEOARTHRITISMusculoskeletal and connective tissue disorders | 1/44 | 1/44 |
| Event | New Formulation for 48 Weeks | Current Formulation for 24 Weeks, New Formulation for 24 Weeks |
|---|---|---|
| NASOPHARYNGITISInfections and infestations | 6/44 | 7/44 |
| CYSTITISInfections and infestations | 4/44 | 2/44 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 4/44 | 4/44 |
| RHEUMATOID ARTHRITISMusculoskeletal and connective tissue disorders | 3/44 | 4/44 |
| DYSPEPSIAGastrointestinal disorders | 3/44 | 3/44 |
| ORAL HERPESInfections and infestations | 3/44 | 2/44 |
| ASPARTATE AMINOTRANSFERASE INCREASEDInvestigations | 2/44 | 3/44 |
| BACK PAINMusculoskeletal and connective tissue disorders | 0/44 | 3/44 |
| HEADACHENervous system disorders | 3/44 | 3/44 |
All participants who received at least 1 dose of study drug
| Age, Continuous(years) | New Formulation for 48 Weeks | Current Formulation for 24 Weeks, New Formulation for 24 Weeks | Total |
|---|---|---|---|
| Mean | 55.7 ± 10.8 | 52.0 ± 12.0 | 53.9 ± 11.5 |
| Sex: Female, Male(Participants) | New Formulation for 48 Weeks | Current Formulation for 24 Weeks, New Formulation for 24 Weeks | Total |
|---|---|---|---|
| Female | 37 | 37 | 74 |
| Male | 7 | 7 | 14 |
The record gives a start of Dec 2012, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab
AbbVie (prior sponsor, Abbott) →